← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $168B	2,075	+16	+0.8%	$145B
2	2 Amgen AMGN $235B	1,601	+60	+4%	$95.6B
3	3 Eli Lilly LLY $1.12T	1,250	+38	+3%	$70.7B
4	4 Becton Dickinson BDX $52.8B	1,066	+33	+3%	$31.9B
5	5 McKesson MCK $117B	890	+1	+0.1%	$27.2B
6	6 Conagra Brands CAG $6.77B	695	-1	-0.1%	$13.3B
7	7 Teva Pharmaceutical Industries Limited TEVA $47.9B	688	-51	-7%	$18.6B
8	8 Regeneron Pharmaceuticals REGN $82B	579	+3	+0.5%	$27.9B
9	9 DaVita DVA $12.1B	482	+3	+0.6%	$11.1B
10	10 Novo Nordisk NVO $173B	463	-20	-4%	$5.53B
11	11 AstraZeneca AZN $258B	462	+12	+3%	$11.1B
12	12 Lamb Weston LW $7.47B	452	+3	+0.7%	$4.85B
13	13 ResMed RMD $34.1B	375	+13	+4%	$6.25B
14	14 West Pharmaceutical WST $27B	295	+7	+2%	$5.44B
15	15 Accendra Health ACH $20.1M	284	-1	-0.4%	$2.11B
16	16 Opko Health OPK $1.2B	245	-11	-4%	$1.05B
17	17 DELISTED CATALENT, INC. CTLT	209	+3	+1%	$3.64B
18	18 Herbalife HLF $1.53B	201	-9	-4%	$6.09B
19	19 Fresenius Medical Care FMS $11.8B	186	+1	+0.5%	$697M
20	20 Tootsie Roll Industries TR $2.88B	173	-9	-5%	$512M
21	21 Medifast MED $135M	167	+5	+3%	$486M
22	22 DELISTED WW International WW	138	0	0%	$866M
23	23 Lexicon Pharmaceuticals LXRX $734M	137	-9	-6%	$1.64B
24	24 Dr. Reddy's Laboratories RDY $10.8B	134	-30	-18%	$1B
25	ARNA 25 DELISTED Arena Pharmaceuticals Inc ARNA	126	-2	-2%	$163M